Agilent Technologies (NYSE:A) Shares Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of Agilent Technologies, Inc. NYSE: A. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in Agilent Technologies stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

Agilent Technologies Stock Performance

A traded down $0.18 on Friday, reaching $120.17. 1,972,723 shares of the stock were exchanged, compared to its average volume of 1,755,995. The company's 50-day moving average price is $116.45 and its 200 day moving average price is $121.55. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. The firm has a market capitalization of $34.14 billion, a PE ratio of 29.67, a PEG ratio of 3.65 and a beta of 1.23.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.05. The company had revenue of $1.67 billion during the quarter, compared to analysts' expectations of $1.63 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. The firm's revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.22 EPS. As a group, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st were given a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, July 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.83%. Agilent Technologies's dividend payout ratio is currently 24.44%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Agilent Technologies by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company's stock valued at $3,908,141,000 after purchasing an additional 240,965 shares during the period. Wellington Management Group LLP raised its position in Agilent Technologies by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company's stock valued at $1,250,276,000 after purchasing an additional 59,781 shares during the period. Geode Capital Management LLC raised its position in Agilent Technologies by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company's stock valued at $938,291,000 after purchasing an additional 53,992 shares during the period. Pictet Asset Management Holding SA raised its position in Agilent Technologies by 2.5% in the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock valued at $624,888,000 after purchasing an additional 128,131 shares during the period. Finally, Generation Investment Management LLP raised its position in Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock valued at $582,976,000 after purchasing an additional 824,243 shares during the period. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on A shares. Barclays lifted their price objective on Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research note on Tuesday, June 24th. Wall Street Zen upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. Robert W. Baird lowered their price objective on Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a report on Thursday, May 22nd. Wells Fargo & Company lowered their price objective on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Finally, UBS Group lowered their price objective on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a report on Thursday, May 29th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, Agilent Technologies presently has a consensus rating of "Moderate Buy" and a consensus target price of $139.77.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.